Dr. Alan Homans, M.D.

Pediatric Hematology & Oncology Physician in Burlington, VT

NPI: 1760408009
Get Contact Info for Free

Primary Practice Location

—

111 Colchester Ave, Burlington, Vermont, 05401

email

Email

Get M.D. Alan's Emailcall

HQ Phone

Get M.D. Alan's Phone Numberphone_android

Mobile

Get M.D. Alan's Mobile
Overview
EHR
Specialty
Certifications
Education
Publications
Clinical Trials
About Dr. Alan Homans, M.D.
numbersNPI
1760408009
emailEmail
Get Email for Free
phone_androidMobile
Get Mobile for Free
callCorporate Phone
Get Phone for Free
Technology Used by Dr. Alan Homans, M.D.
Which EHR is used by Dr. Alan Homans, M.D.?
Dr. Alan Homans, M.D. uses *** EHR.
Unlock Technology Stack

Looking to connect with more Physicians?

Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.

Get Started for Free
Dr. Alan Homans, M.D. Specialties
PRIMARY SPECIALTY
Pediatric Hematology & Oncology PhysicianTaxonomy: 2080P0207XState: VT
SUBSPECIALTIES
Pediatric Hematology-Oncology
Dr. Alan Homans, M.D. Certifications & Licensure
STATE LICENSES
V

VT State Medical License

Dr. Alan Homans, M.D. Education & Trainingkeyboard_arrow_up
UC

UMass Chan Medical School

umassmed.edu

Residency • Pediatrics

1981 - 1982

Dr. Alan Homans, M.D. Publications

Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab.

Authors: Carl Nelson, Alissa Thomas, Suzanne Tucker, Susan Durham

Journal: Pediatr Blood Cancer

Publication Date: 2018-09-25

BevacizumabAdolescentAntineoplastic Combined Chemotherapy ProtocolsAstrocytomaBrain NeoplasmsFemale

Randomized Waitlist-Control Trial of a Web-Based Stress-Management and Resiliency Program for Adolescent and Young Adult Cancer Survivors: Protocol for the Bounce Back Study.

Authors: Natasha Frederick, John Denninger, Jeffrey Peppercorn, Annah Abrams, Lisa Kenney, Ghazala Usmani

Journal: JMIR Res Protoc

Publication Date: 2022-01-26

Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.

Authors: Susan Colace, Mark Applebaum, Margaret Macy, Junne Kamihara, Amit Sabnis, Luke Maese, Suzanne Forrest, Brian Crompton, Theodore Laetsch, Daniel Weiser, Julia Glade Bender

Journal: Nat Med

Publication Date: 2022-06-23

AdolescentAdultChildChild, PreschoolHumansInfant
See All 6 Publications By Dr. Alan Homans, M.D.arrow_outward
Dr. Alan Homans, M.D. Clinical Trials10 Clinical Trialskeyboard_arrow_up
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
ACTIVE_NOT_RECRUITING

Lead Sponsor: Children's Oncology Group

Collaborators: National Cancer Institute (NCI), EsPhALL

Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Laboratory Biomarker Analysis, DRUG: Doxorubicin, DRUG: Dexamethasone, DRUG: Cyclophosphamide, DRUG: Cytarabine, DRUG: Ifosfamide, DRUG: Etoposide, DRUG: Vincristine Sulfate, DRUG: Methotrexate, DRUG: Methylprednisolone, BIOLOGICAL: Filgrastim, PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation, DRUG: Mercaptopurine, DRUG: Calaspargase Pegol, DRUG: Prednisolone, DRUG: Imatinib Mesylate, DRUG: Therapeutic Hydrocortisone, DRUG: Thioguanine, DRUG: Pegaspargase, DRUG: Leucovorin Calcium, DRUG: Daunorubicin Hydrochloride, DRUG: Levoleucovorin, DRUG: Dexrazoxane Hydrochloride

Conditions:Mixed Phenotype Acute LeukemiaT Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
ACTIVE_NOT_RECRUITING

Lead Sponsor: National Cancer Institute (NCI)

Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Laboratory Biomarker Analysis, RADIATION: Radiation Therapy, DRUG: Cyclophosphamide, DRUG: Vincristine Sulfate, BIOLOGICAL: Dactinomycin, DRUG: Vinorelbine, DRUG: Temsirolimus, DRUG: Irinotecan Hydrochloride

Conditions:RhabdomyosarcomaAlveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal RhabdomyosarcomaSclerosing RhabdomyosarcomaSpindle Cell Rhabdomyosarcoma
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
ACTIVE_NOT_RECRUITING

Lead Sponsor: National Cancer Institute (NCI)

Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, OTHER: Quality-of-Life Assessment, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Brentuximab Vedotin, DRUG: Etoposide, DRUG: Vincristine Sulfate, DRUG: Methylprednisolone, BIOLOGICAL: Bleomycin Sulfate, DRUG: Doxorubicin Hydrochloride

Conditions:Ann Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage IIIB Hodgkin LymphomaAnn Arbor Stage IVA Hodgkin LymphomaAnn Arbor Stage IVB Hodgkin LymphomaClassic Hodgkin LymphomaChildhood Hodgkin Lymphoma
Dr. Alan Homans, M.D. Practice Locations
University of Vermont Medical CenterAffiliated
Hospital • Burlington, VT

Frequently asked questions regarding Dr. Alan Homans, M.D.

Dr. Alan Homans, M.D.'s email address is available to verified Dmand AI users. Sign up for a free trial to reveal their direct contact information.
Dr. Alan Homans, M.D.'s direct phone number is available to Dmand AI subscribers. To access their direct number, start a free trial.
Dr. Alan Homans, M.D. is a Pediatric Hematology & Oncology Physician physician currently practicing at 111 Colchester Ave in Burlington, Vermont. They hold admitting privileges at 1 hospital(s), including University of Vermont Medical Center. To see all the affiliations of Dr. Alan Homans, M.D., start a free trial.
Dr. Alan Homans, M.D. is a board-certified Pediatric Hematology & Oncology Physician physician with a subspecialty in Pediatric Hematology-Oncology.
Dr. Alan Homans, M.D.'s procedure data is available to Dmand AI subscribers.
Dr. Alan Homans, M.D.'s National Provider Identifier (NPI) is 1760408009. This is a public identifier issued by CMS and can be verified at the NPPES NPI Registry. Their primary taxonomy code is 2080P0207X, corresponding to Pediatric Hematology & Oncology Physician.
The EHR and practice technology used by Dr. Alan Homans, M.D. at is available to Dmand AI subscribers. Sign up for a free trial to unlock the full technology stack.
Dr. Alan Homans, M.D.'s insurance and payer details are available to Dmand AI subscribers.
Dr. Alan Homans, M.D. holds hospital privileges at 1 institution(s). Their primary affiliation is University of Vermont Medical Center in Burlington, Vermont.
Dr. Alan Homans, M.D.'s board certification details are available to Dmand AI subscribers.
Dr. Alan Homans, M.D.'s education history is available to Dmand AI subscribers.
Dr. Alan Homans, M.D.'s patient volume data is available to Dmand AI subscribers.
Dr. Alan Homans, M.D. is affiliated with University of Vermont Medical Center, a large (20+ physician) practice with 1787 physicians based in Burlington, Vermont. The practice is independently owned.
Dr. Alan Homans, M.D. has 6 indexed publications on record and has been listed as a principal investigator on 10 clinical trial(s). Their research activity is available to Dmand AI subscribers. Sign up for a free trial to unlock their full research activity.

Start today — no contract required

Identify. Engage. Convert. 

Stop stitching together Definitive, ZoomInfo, and a separate outreach tool. Dmand gives Health IT GTM teams everything they need to find verified healthcare providers and executives, enrich contacts, and book more meetings — in one platform.
Try for freearrow_outwardBook a Demo